Personalized Antigen Receptor with Cell Therapy (CAR-T)

Yıl 2019, , 2235 - 2245, 01.12.2019

Özlem Gök , Abdullah Aslan

https://doi.org/10.21597/jist.591578

Cited By: 1

Öz

Given the use of the body's own immune system, immunotherapy; promises a more effective and durable treatment than traditional treatments to treat cancer. A type of immunotherapy chimeric antigen receptor-T (CAR-T) cell therapy is a promising new T cell immunotherapy in cancer treatment. CAR-T a fusion protein comprising an antigen recognition fragment and T cell signaling sites. CAR-T cell, predominantly; acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), lymphoma (lymph cancer), multiple myeloma (bone marrow cancer) have been used in the treatment of hematological cancers. CAR-T cell; melanoma (skin cancer), breast cancer and sarcoma (tumor in the connective tissue), such as the treatment of tumors promises great promise. Studies are underway to improve chimeric antigen receptor technology to increase safety and efficacy, reduce production costs and make it more applicable than hematological cancers, and the number of clinical trials continues to grow exponentially.

Anahtar Kelimeler

immünoterapi, kimerik antijen reseptörü, T lenfosit

Kişiye Özgü Geliştirilen Antijen Reseptörü ile Hücre Tedavisi (CAR-T)

Öz

Vücudun kendi bağışıklık sisteminin kullanımı göz önüne alındığında, immünoterapi olarak adlandırılan tedavi; kanseri tedavi etmek için geleneksel tedavilerden daha etkili ve dayanıklı bir tedavi vaat etmektedir. Bir tür immünoterapi olan kimerik antijen reseptörü-T (CAR-T) hücre tedavisi, kanser tedavisinde umut verici yeni bir T hücresi immünoterapisidir. CAR-T; bir antijen tanıma parçası ve T hücresi sinyalleşme alanlarından oluşan bir füzyon proteinidir. CAR-T hücresi, ağırlıklı olarak; akut lenfoblastik lösemi (ALL), kronik lenfositik lösemi (KLL), lenfoma (Lenf kanseri), multipl miyeloma (kemik iliği kanseri) dahil olmak üzere hematolojik kanserlerin tedavisinde kullanılmıştır. CAR-T hücresi; melanom (cilt kanseri), meme kanseri ve sarkom (bağ dokusunda oluşan tümör) gibi tümörlerin tedavisinde ise büyük umut vaat etmektedir. Güvenlik ve etkinliği artırmak, üretim maliyetlerini azaltmak ve hematolojik kanserlerin ötesinde uygulanabilir kılmak için kimerik antijen reseptörü teknolojisinin iyileştirilmesine yönelik çalışmalar yürütülmekte ve klinik çalışmaların sayısı katlanarak artmaya devam etmektedir.

Anahtar Kelimeler

İmmünoterapi, kimerik antijen reseptörü, T lenfosit

Kaynakça

• Arabi F, Torabi-Rahvar M, Shariati A, Ahmadbeigi N, Naderi M, 2018. Antigenic Targets of CAR T Cell Therapy. A Retrospective View on Clinical Trials, Experimental Cell Research, 369: 1–10.
• Ataca P, Arslan Ö, 2015. Chimeric Antigen Receptor T Cell Therapy in Hematology. Turk J Hematol, 32: 285-294.
• Bao F, Wan W, He T, Qi F, Liu G, Hu K, Lu X, Yang P, Dong F, Wang J, Jing H, 2019. Autologous CD19-Directed Chimeric Antigen Receptor-T Cell is An Effective and Safe Treatment to Refractory or Relapsed Diffuse Large B-Cell Lymphoma. Cancer Gene Therapy, 1-8.
• Başaran A, 2010. Tıbbi Biyoloji. Feryal Matbaacılık, Ankara-Türkiye.
• Baybutt TR, Flickinger JC, Caparosa EM, Snook AE, 2019. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors. Clinical Pharmacology & Therapeutics, 105(1): 71-78.
• Bollino D, Webb TJ, 2017. Chimeric Antigen Receptor–Engineered Natural Killer and Natural Killer T Cells for Cancer Immunotherapy. Translational Research, 187: 32–43.
• Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR, 2018. Chimeric Antigen Receptor (CAR) T Therapies for the Treatment of Hematologic Malignancies: Clinical Perspective and Significance. Journal for Immuno Therapy of Cancer, 6(137): 1-12.
• Brudno JN, Kochenderfer JN, 2019. Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management. Blood Reviews, 34: 45-55.
• Calmels B, Mfarrej B, Chabannon C, 2018. From Clinical Proof-of-Concept to Commercialization of CAR T Cells. Drug Discovery Today, 23(4): 758-762.
• Chen Y, E CY, Gong ZW, Liu S, Wang ZX, Yang YS, Zhang XW, 2018. Chimeric Antigen Receptor-Engineered T-Cell Therapy for Liver Cancer. Hepatobiliary & Pancreatic Diseases International, 17: 301–309.
• Enblad G, Karlsson H, Gammelgard G, Wenthe J, Lövgren T, Amini RM, Wikstrom KI, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A, 2018. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clinical Cancer Research, 24: 6185-6194.
• Gauthier J, Yakoub-Agha I, 2017. Chimeric Antigen-Receptor T-Cell Therapy for Hematological Malignancies and Solid Tumors: Clinical Data to Date, Current Limitations and Perspectives. Current Research in Translational Medicine, 65: 93–102.
• Gee AP, 2018. GMP CAR-T Cell Production. Best Practice & Research Clinical Haematology, 31: 126-134.
• Ghobadi A, 2018. Chimeric Antigen Receptor T Cell Therapy for Non-Hodgkin Lymphoma. Current Research in Translational Medicine, 66: 43–49.
• Gomes-Silva D, Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M, Lulla P, Rouce RH, Cabral JMS, Ramos CA, Brenner MK, Mamonkin M, 2019. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Molecular Therapy, 27(1): 272-280.
• Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, Albon SJ, Casanovas-Company J, Castro F, Popova B, Villanueva K, Yeung J, Vetharoy W, Guvenel A, Wawrzyniecka PA, Mekkaoui L, Cheung GW, Pinner D, Chu J, Lucchini G, Silva J, Ciocarlie O, Lazareva A, Inglott S, Gilmour KC, Ahsan G, Ferrari M, Manzoor S, Champion K, Brooks T, Lopes A, Hackshaw A, Farzaneh F, Chiesa R, Rao K, Bonney D, Samarasinghe S, Goulden N, Vora A, Veys P, Hough R, Wynn R, Pule MA, Amrolia P, 2019. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nature Medicine, 25(9):1408-1414.
• Grupp S, 2018. Beginning the CAR T Cell Therapy Revolution in the US and EU. Current Research in Translational Medicine, 66(2): 62-64.
• Han X, Wang Y, Han WD, 2018. Chimeric Antigen Receptor Modified T-Cells for Cancer Treatment. Chronic Diseases and Translational Medicine, xx: 1-19.
• Hucks G, Rheingold SR, 2019. The Journey to CAR T Cell Therapy: The Pediatric and Young Adult Experience with Relapsed or Refractory B-ALL. Blood Cancer Journal, 9(10): 1-9.
• Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS, 2018. Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. Journal of Thoracic Oncology, 13(1): 16-26.
• Labanieh L, Majzner LG, Mackall CL, 2018. Programming CAR-T Cells to Kill Cancer. Nature Biomedical Engineering, 2: 377–391.
• Long KB, Young RM, Boesteanu AC, Davis MM, Melenhorst JJ, Lacey SF, Garamo DA, Levine BL, Fraietta JA, 2018. CAR T Cell Therapy of Non-Hematopoietic Malignancies: Detours on the Road to Clinical Success. Frontiers in Immunology, 9(2740): 1-13.
• Mirzaei HR, Pourghadamyari H, Rahmati M, Mohammadi A, Nahand JS, Rezaei A, Mirzaei H, Hadjati J, 2018. Gene-Knocked Out Chimeric Antigen Receptor (CAR) T Cells: Tuning up for the Next Generation Cancer Immunotherapy. Cancer Letters, 423: 95-104.
• Mollanoori H, Shahraki H, Rahmati Y, Teimourian S, 2018. CRISPR/Cas9 and CAR-T Cell, Collaboration of Two Revolutionary Technologies in Cancer Immunotherapy, An Instruction for Successful Cancer Treatment. Human Immunology, 79: 876-882.
• Nair R, Neelapu SS, 2018. The Promise of CAR T-Cell Therapy in Aggressive B-Cell Lymphoma. Best Practice & Research Clinical Haematology, 31: 293–298.
• Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ, 2018. Chimeric Antigen Receptor T-Cell Therapy - Assessment and Management of Toxicities. Nature Reviews Clinical Oncology, 15: 47–62.
• Pawar D, Molinaro J, Knight J, Heinrich T, 2018. Toxicities of CAR T-Cell Therapy and the Role of the Consultation-Liaison Psychiatrist. Psychosomatics, 1-5.
• Perica K, Curran KJ, Brentjens RJ, Giralt SA, 2018. Building A CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products At Memorial Sloan Kettering Cancer Center. Biology of Blood and Marrow Transplantation, 24(6): 1135–1141.
• Ramachandran M, Dimberg A, Essand M, 2017. The Cancer-Immunity Cycle As Rational Design for Synthetic Cancer Drugs: Novel DC Vaccines and CAR T-Cells. Seminars in Cancer Biology, 45: 23–35.
• Rossig C, 2018. CAR T Cell Immunotherapy in Hematology and Beyond. Clinical Immunology, 186: 54–58.
• Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A, 2017. CRISPR/Cas9-Mediated PD-1 Disruption Enhances Anti-Tumor Efficacy of Human Chimeric Antigen Receptor T Cells. Scientific Reports, 7(737): 1-10.
• Schmidts A, Maus MV, 2018. Making CAR T Cells a Solid Option for Solid Tumors. Frontiers in Immunology, 9(2593): 1-10.
• Shaw AR, Porter CE, Watanabe N, Tanoue K, Sikora A, Gottschalk S, Brenner MK, Suzuki M, 2017. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Molecular Therapy, 25(11): 2440-2451.
• Si W, Li C, Wei P, 2018. Synthetic Immunology: T-Cell Engineering and Adoptive Immunotherapy. Synthetic and Systems Biotechnology, 3: 179–185.
• Siddiqi HF, Staser KW, Nambudiri VE, 2018. Research Techniques Made Simple: CAR T-Cell Therapy. Journal of Investigative Dermatology, 138: 2501-2504.
• Songu M, Katılmış H, 2012. Enfeksiyondan Korunma ve İmmün Sistem. Jornal of Medical Updates, 2(1): 31-42.
• Tariq SM, Haider SA, Hasan M, Tahir A, Khan M, Rehan A, Kamal A, 2018. Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer. Cureus, 10(10): 1-11.
• Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O, Soond SM, Piacentini M, Melino G, Zaritskey A, Barlev NA, 2018. The Biological Basis and Clinical Symptoms of CAR-T Therapy-Associated Toxicites. Cell Death and Disease, 9(897): 1-15.
• Tokarew N, Ogonek J, Endres S, Bergwelt-Baildon MV, Kobold S, 2018. Teaching An Old Dog New Tricks: Next-Generation CAR T Cells. British Journal of Cancer, 1-12.
• Wang X, Rivière I, 2016. Clinical Manufacturing of CAR T Cells: Foundation of A Promising Therapy. Molecular Therapy Oncolytics, 3: 1-7.
• Xu H, Cao W, Huang L, Xiao M, Cao Y, Zhao L, Wang N, Zhou J, 2018. Effects of Cryopreservation on Chimeric Antigen Receptor T Cell Functions. Cryobiology, 83: 40–47.
• Zhang L, Sosinowski T, Cox AR, Cepeda JR, Sekhar NS, Hartig SM, Miao D, Yu L, Pietropaolo M, Davidson HW, 2019. Chimeric antigen receptor (CAR) T Cells Targeting A Pathogenic MHC Class II: Peptide Complex Modulate the Progression of Autoimmune Diabetes. Journal of Autoimmunity, 96: 50–58.
• Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M, 2018. The Application of CAR-T Cell Therapy in Hematological Malignancies: Advantages and Challenges. Acta Pharmaceutica Sinica, 8(4): 539-551.
• Zheng Y, Gao N, Fu YL, Zhang BY, Li XL, Gupta P, Wong AJ, Li TF, Han SY, 2018. Generation of Regulable EGFRvIII Targeted Chimeric Antigen Receptor T Cells for Adoptive Cell Therapy of Glioblastoma. Biochemical and Biophysical Research Communications, 507: 59-66.